Form 4: Madrigal Director Sells Shares After Option Exercise

Madrigal Pharmaceuticals Director Richard S. Levy exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Summary

• Richard S. Levy, a Director of Madrigal Pharmaceuticals, Inc. (MDGL), reported transactions on November 13, 2025.
• Levy exercised stock options to acquire 2,500 shares of common stock at an exercise price of $7.36 per share.
• He also exercised stock options to acquire an additional 6,000 shares of common stock at an exercise price of $16.46 per share.
• Immediately following the option exercises, Levy sold a total of 8,400 shares of common stock in multiple transactions.
• The sales were executed at weighted average prices ranging from $514.674 to $530.21 per share.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025.
• Following these transactions, Levy's direct beneficial ownership of common stock decreased from 29,697 shares to 21,197 shares.
• He retains 4,000 unexercised stock options.

Sentiment

Score: 5

Explanation: The transactions represent a pre-planned exercise of stock options and subsequent sale of shares by a director, which is a common practice for insider compensation and portfolio diversification. The sales were executed under a Rule 10b5-1 plan, suggesting a scheduled divestment rather than a reaction to new, undisclosed information, leading to a neutral sentiment.

Positives

• The director realized significant gains by exercising options at low strike prices ($7.36 and $16.46) and selling shares at high market prices (over $514).
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new information.

Negatives

• Insider selling, even if pre-planned, reduces the director's direct equity stake in the company, which some investors might interpret as a reduction in future confidence.

Future Outlook

Not applicable for this type of filing, which reports individual insider transactions rather than company-wide financial guidance or strategic outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information to analyze broader industry trends or competitors.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe a reduction in direct insider ownership, which could be interpreted differently depending on individual investment philosophies. The pre-planned nature of the sales mitigates some concerns regarding the timing of the divestment.

Key Dates

Recommendation

The filing details a director's exercise of stock options and subsequent sale of shares under a pre-arranged Rule 10b5-1 trading plan. This is a common and often routine event for insiders to manage their equity compensation and diversify their portfolios. While it represents a reduction in direct insider ownership, the pre-planned nature suggests it is not driven by new, negative information about the company. Therefore, it does not provide a strong signal for a 'buy' or 'sell' recommendation, warranting a 'hold' as it is a planned transaction rather than a reactive one.

Keywords

Madrigal Pharmaceuticals, MDGL, Richard S. Levy, Form 4, insider trading, stock options, Rule 10b5-1 plan, beneficial ownership, director, equity sale